Abstract: 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.

Abstract: An activator of PPAR&ggr; (such as pioglitazone) is useful for the treatment of a condition affecting the skin characterised by disordered fibroblast or myofibroblast function, excessive matrix production, modular fasciitis or Dupuytren's Contracture. The invention is particularly useful for treating keloids and hypertrophic scarring.

Abstract: 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.

Abstract: The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.

Abstract: The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.

Abstract: The present invention pertains to a unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.

Abstract: Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide) is useful as an anesthetic, particularly in a patient who is disposed to adverse systemic side-effects, e.g., one who is CNS-compromised or predisposed to CNS side-effects. A unit dose of levobupivacaine comprising at least 75 mg to less than 200 mg of levobupivacaine is described herein.

Abstract: A pharmaceutical dosage form comprises, in one portion thereof, a substantially single (+)-enantiomer of a chiral drug other than verapamil and, in another, separate portion thereof, a substantially single (−)-enantiomer of the drug wherein, in use, the different enantiomers are released at different rates from the dosage form. The dosage form is useful for administration of chiral drugs where both enantiomers have a valid pharmacological input, and where a clinical benefit may be realised by controlling the release rates of those enantiomers. Examples of such drugs include, in particular, tramadol and warfarin.

Abstract: Aqueous pharmaceutical compositions comprising levobupivacaine((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide ), that are particularly useful in a patient who is disposed to adverse systemic side-effects, are disclosed.

Abstract: A pharmaceutical dosage form comprises, in one portion thereof, a substantially single (+)-enantiomer of a chiral drug other than verapamil and, in another, separate portion thereof, a substantially single (-)-enantiomer of the drug wherein, in use, the different enantiomers are released at different rates from the dosage form. The dosage form is useful for administration of chiral drugs where both enantiomers have a valid pharmacological input, and where a clinical benefit may be realised by controlling the release rates of those enantiomers. Examples of such drugs include, in particular, tramadol and warfarin.

Abstract: The present invention concerns the use of levobupivacaine for the treatment of chronic pain in a patient. Levobupivacaine used in the subject methods is substantially free of dexbupivacaine. The methods of the invention can be used, for example, to treat pain in patients that are cardiac compromised, suffering from central nervous system damage or cancer.

Abstract: Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide) is useful as an anesthetic, particularly in a patient who is CNS-compromised or predisposed to CNS side-effects. It is also useful as an anesthetic in obstetrics.

Abstract: This application relates to methods of using levobupivacaine substantially free of dexbupivacaine for anaesthetic treatment of pain in a patient having depressed myocardial contractility.